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ABSTRACT
The use of next-generation sequencing
technologies to produce genomic copy number
data has recently been described. Most approaches,
however, reply on optimal starting DNA, and are
therefore unsuitable for the analysis of formalin-
fixed paraffin-embedded (FFPE) samples, which
largely precludes the analysis of many tumour
series. We have sought to challenge the limits of
this technique with regards to quality and quantity
of starting material and the depth of sequencing
required. We confirm that the technique can be
used to interrogate DNA from cell lines, fresh
frozen material and FFPE samples to assess copy
number variation. We show that as little as 5ng of
DNA is needed to generate a copy number
karyogram, and follow this up with data from a
series of FFPE biopsies and surgical samples. We
have used various levels of sample multiplexing to
demonstrate the adjustable resolution of the meth-
odology, depending on the number of samples and
available resources. We also demonstrate reprodu-
cibility by use of replicate samples and comparison
with microarray-based comparative genomic
hybridization (aCGH) and digital PCR. This tech-
nique can be valuable in both the analysis of
routine diagnostic samples and in examining large
repositories of fixed archival material.
INTRODUCTION
Systems medicine is expected to link complex molecular
data underlying disease phenotypes to patient outcomes
(1). As technology for data generation, such as
next-generation (NG) sequencing, and methodology for
computational analysis develop rapidly, the accessibility
of clinical material of suﬃcient quality and quantity is
likely to be rate limiting in the discovery process. For
cancer patients, diagnosis is virtually always based on
the evaluation of a tumour sample, ideally a biopsy or
surgical specimen. Left-over tissue, stored in pathology
archives and no longer required following diagnosis or
clinical management, proves an immense resource for mo-
lecular analysis, as each cancer patient is a potential
donor. The ﬁxation procedures, necessary for tissue pres-
ervation in the diagnostic setting, may however comprom-
ise the quality of the material with regard to some
applications. One of the applications described for NG
sequencing is the production of copy number variation
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to a reference genome (2–5). These initial studies have
used a depth of sequencing that would preclude the
routine analysis of large numbers of samples. They have
also used optimal starting conditions in terms of DNA
quality and quantity, which are not likely with clinical
samples. However, Schweiger et al. (6) recently showed
that DNA isolated from formalin-ﬁxed paraﬃn-embedded
(FFPE) tumours could be used for sequencing-based CNV
analysis. Here, we report how we have modiﬁed the
current methods for sequencing-based CNV analysis and
overcome their limitations, to allow the high-throughput
copy number analysis of DNA from suboptimal quality
material, such as FFPE tissue. Speciﬁcally, we have
investigated the feasibility of undertaking sequence
analysis of samples in pools using unique oligonucleotide
tags to distinguish individual patients. We demonstrate
that up to 10 patient samples can be pooled in one
sequencing lane of an Illumina Genome Analyzer II
(GAII; Illumina Inc, San Diego, CA, USA). We also
show that as little as 5ng (compared to Illumina’s recom-
mended 1mg) of template DNA from FFPE specimens is
suﬃcient to generate a library of fragments for sequence
analysis, resulting in a copy number karyogram that is
indistinguishable from a karyogram generated from 1mg
of template DNA or from DNA isolated from the same
fresh-frozen tumours without prior ﬁxation. These modi-
ﬁcations will enable exploitation of the vast archives of
FFPE material to supply the systems medicine research
pipeline, and will bring this methodology within the
reach of routine clinical analysis, while preserving the
majority of the tissue block for other investigations.
To illustrate the value of this approach, we have
obtained FFPE samples of repeat biopsies and resection
specimens from the same patient whose oral cancer
recurred over a 2-year period. We show that all samples
share certain copy number aberrations indicating a likely
common progenitor, but that the most recent samples
display a new region of chromosomal ampliﬁcation
indicating that an initial clonal population of tumour
cells has continued to mutate.
MATERIALS AND METHODS
Sample selection
Cell lines. LUDLU-1 cell line was established from a lung
squamous cell carcinoma (7). AGLCL cell line was estab-
lished following EBV infection of normal B cells from the
same patient. Both cell lines were cultured in RPMI 1640
medium supplemented with 2mM glutamine, 50 U/ml
penicillin, 50mg/ml streptomycin and 10% foetal bovine
serum using standard cell culture techniques. The
HONE-1 cell line is an epithelial cell line derived from a
poorly diﬀerentiated nasopharyngeal squamous cell car-
cinoma (8). It was cultured in Iscove’s modiﬁed
Dulbecco’s medium, supplemented with 2mM glutamine,
50 U/ml penicillin, 50mg/ml streptomycin and 10% foetal
bovine serum using standard cell culture techniques.
Clinical samples. Surgical resection specimens of lung
tumours and corresponding normal lung tissue were pro-
spectively collected at the local Department of Thoracic
Surgery, snap frozen and stored in aliquots at 80C.
FFPE blocks of lung tumours, oral tumours and dysplas-
tic lesions were retrieved from the local pathology archive.
Approval was obtained from the local ethics committee
and written informed consent for the use of their tissue
for research was available for all patients.
DNA isolation
Snap-frozen tissues and cell lines. Genomic DNA from
clinical samples and cell lines was prepared by sequential
phenol/chloroform extraction followed by ethanol precipi-
tation, adapted from a previously described method (9).
Brieﬂy, frozen tissue was ground using pestle and mortar
and the resulting powder suspended in 0.4% LiDS lysis
buﬀer; cell lines were harvested from the culture ﬂask,
pelletted by centrifugation and resuspended in 0.4%
LiDS lysis buﬀer. Proteinase K was then added to the
cell lysate to a ﬁnal concentration of 100mg/ml and
incubated overnight at 55C. Following three phenol ex-
tractions and one with chloroform, the ﬁnal aqueous
solution was added with 0.3M sodium acetate pH 5.2
(1:10 vol:vol) and DNA precipitated by the addition of
two volumes of 95% ethanol. The DNA precipitate was
then collected by centrifugation, washed with 70%
ethanol, air dried and ﬁnally dissolved in sterile water.
FFPE tissue sections. Areas of dysplasia or tumour to be
dissected were identiﬁed and marked by a pathologist on
an haematoxylin and eosin (H+E) stained slide cut from
each FFPE block to be sampled. Ten 7mm sections were
then cut and the dysplastic or tumour tissue was
macro-dissected with a scalpel blade using the marked
H+E slide as a guide. A further section was cut and
then H+E stained to conﬁrm persistence of histology
throughout the areas sampled. DNA extraction was per-
formed using the QIAamp DNA micro kit (Qiagen,
Sussex, UK) according to the manufacturer’s instructions
and DNA was eluted in 25ml of AE Buﬀer.
DNA concentration and purity was determined using
the Nanodrop-8000 (Fisher Scientiﬁc UK Ltd,
Leicestershire, UK) and the Quant-iT PicoGreen
dsDNA BR assay (Invitrogen, Paisley, UK).
Array-CGH
DNA from the LUDLU-1 and AGLCL cell lines (450ng
each) was labelled in the presence of Cy3-or Cy5-labelled
nucleotides as previously described (10) but puriﬁed using
a PureLink PCR Puriﬁcation Kit (Invitrogen) according
to the manufacturer’s instructions. Labelled material was
combined, hybridized to Agilent Human Genome 244K
CGH microarrays (Agilent Technologies, Santa Clara,
CA, USA), washed and scanned according to Agilent’s
Oligonucleotide Array-based CGH for Genomic DNA
Analysis protocol. Data were extracted from the scanned
images using Feature Extraction software (v7.1; Agilent
Technologies) and analysed using Agilent’s DNA
Analytics package.
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Between 5ng and 1mg genomic DNA were used to prepare
the DNA libraries for sequencing, following standard
Illumina protocols. DNA was sheared on a Covaris S2
Sample Preparation System (Covaris Inc., Woburn, MA,
USA) and checked for appropriate size distribution on an
Agilent Bioanalyser DNA 1000 LabChip. End repair was
performed by using the End-It DNA End Repair Kit
(Epicentre Biotechnologies, Madison, WI, USA) and
Klenow DNA polymerase, followed by ligation of 6bp
unique tag adapter oligonucleotides, using previously es-
tablished methods (11). Tags were chosen so as to avoid
over-representation of any one base at each position,
which can interfere with cluster recognition. Fragments
were size selected to 200bp using a gel cut step. Samples
were enriched using a 12-cycle enrichment PCR. For low
concentration DNA samples, an 18-cycle enrichment PCR
was performed before the gel cut stage rather than after-
wards. Libraries were then examined using an Agilent
Bioanalyser DNA 1000 LabChip and Invitrogen’s
Quant-iT Picogreen dsDNA BR assay kit to assess for
DNA quality and concentration, respectively. This infor-
mation was used to pool equal amounts of each sample
library for cluster ampliﬁcation and either 51 or 76 cycles
of Illumina sequencing by synthesis, resulting in 45/70bp
of genomic DNA sequence and 6bp of tagged adapter.
Sequencing was initially done with 51-bp reads but the
move was made to 76-bp reads as machine and analysis
package upgrades resulted in better base calling for longer
reads.
Data analysis
Image analysis and base calling were performed using
Illumina’s CASAVA pipeline. Reads were trimmed of
their 6bp tags with the USE_BASES option and
uniquely aligned to the human genome (UCSC version
hg19) using the alignment algorithm Eland (12). Python
scripts were used to ﬁrst split the reads into ﬁles according
to tag, and then to make pairwise comparisons of each
tumour and normal sample by splitting the genome into
non-overlapping windows of equal numbers of normal
reads, typically 400, and counting the number of tumour
reads which fell into each window.
Copy number analysis was done in R, ﬁrst by
normalizing the number of tumour and normal counts
across the genome and calculating the log2 ratio of
normalized tumour:normal read counts for each
window. Second, segments of equal copy number were
called using the Bioconductor DNAcopy package (13).
These segments were converted into bedgraphs suitable
for uploading onto the UCSC genome browser
(http://genome.ucsc.edu/) (14) as well as being plotted
over graphs of tumour read counts. A summary of the
number of aligned reads and subsequently detected
CNVs for each sample is listed in Table 1.
A Pearson correlation was calculated between the
array-CGH (aCGH) and sequencing data by calculating
an average aCGH generated copy number for every
genomic window of sequencing reads. This made it
possible to perform a pairwise comparison of two ﬁles
of equal length.
Table 1. Summary statistics for each sample
Sample Aligned
tumour
reads
Fraction
reads
aligning
(percent)
Aligned
normal
reads
Mean
window
size (kb)
Number
of CNVs
Mean CNV
size (Mb)
Minimum
CNV
size (Mb)
LUDLU1 2551569 76 4973483 498 163 18.3 0.56
LS010 0.035X 2330765 75 1894107 653 101 29.2 1.15
LS010 0.016X 1091212 75 888169 1224 78 38.2 1.59
LS010 0.002X 136405 75 882800 1388 47 62.9 6.20
LS035 931088 74 809154 1524 53 57.1 1.35
LS035 FFPE 990577 74 809154 1524 65 45.6 1.84
LS041 888436 70 824869 1417 74 40.2 1.02
LS041 FFPE 169202 64 824869 1417 55 53.7 2.65
LS041 50ng 939186 58 824869 1417 105 27.7 1.43
LS041 10ng 181264 21 824869 1417 94 31 2.39
LS041 5ng 136350 20 824869 1417 107 27.1 2.39
LS043 1002978 60 1259862 895 110 27.3 1.18
LS043 FFPE 511550 76 1259862 895 72 41.2 0.91
LS043 FFPE 50ng 4697581 60 2642990 468 151 19.9 0.47
LS043 FFPE 10ng 2296802 61 2642990 468 194 15.3 0.76
LS043 FFPE 5ng 3570091 62 2642990 468 144 20.9 0.85
PG019-1 879715 76 1894107 653 64 47 1.11
PG019-4 564178 74 1894107 653 105 28.2 1.10
PG019-5 520740 71 1894107 653 70 43 2.23
PG019-6 844130 76 1894107 653 64 47 0.77
PG019-7 303584 57 1894107 653 36 84 2.39
PG019-8 2249010 75 1894107 653 37 81.8 3.89
PG019-9 1305492 77 1894107 653 41 73.7 3.29
The number of aligned reads, fraction of reads aligning, number of reference reads, mean window size and size and number of detected CNVs are
shown
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between molecular copy number counting (MCC) and
sequencing data, sampling the sequence based copy
number for every MCC data point.
RESULTS
Reproducibility and validation of NG sequencing for CNV
analysis
We began by analysing the copy number proﬁle of
genomic DNA from the lung squamous cell carcinoma
cell line LUDLU-1 and the DNA from the paired
normal B cell line AGLCL. We conﬁrmed that the
tumour karyogram demonstrated copy number gain and
loss features predicted for a squamous cell lung carcinoma
such as 3p loss and distal 3q and 8q ampliﬁcation (15–17)
(Supplementary Figure S1). We conﬁrmed by comparing
the normal DNA from ﬁve individuals that comparison of
normal DNA against normal DNA resulted in a feature-
less karyogram with no detectable gain or loss (result not
shown).
Further validation was achieved by comparing the copy
number proﬁle generated by NG sequencing with that
obtained by aCGH. High-resolution aCGH was per-
formed using an Agilent 244K array using DNA from
LUDLU-1 and AGLCL cells. The aCGH-generated
copy number proﬁles appeared almost identical to those
obtained from sequence analysis. Every chromosome
showed the same pattern of gain and loss. Even smaller
features such as small spikes of gain or loss were
replicated. A Pearson correlation of 0.9362277 was
calculated between the two data sets. Examples from the
aCGH proﬁle compared to a copy number karyogram
generated from NG sequencing data is shown in Figure 1.
To determine the validity of copy number annotation
by sequencing even at high resolution, we compared its
performance to another method that also generates copy
number data in a digital format, MCC (18,19). We
compared the copy number proﬁle generated by NG
sequencing with the MCC data for the 17 Mb amplicon
in the distal part of chromosome 3q in the HONE-1 cell
line and found the proﬁles to be very similar. Gains and
losses were seen in the same places, although the MCC
data were noisier and suggested a slightly higher copy
number in places. A Pearson correlation of 0.8126372
was calculated between the two data sets (Figure 2).
The reproducibility of copy number data produced
from NG sequencing was conﬁrmed by demonstrating vir-
tually identical copy number karyograms on analysis of
duplicates of four sets of DNA from tumour:normal pairs
of fresh frozen lung squamous cell carcinomas
(Supplementary Figure S2).
Figure 1. Examples of a comparison of copy number analysis by sequencing and aCGH. (a) Chromosome 3 analysed by NG sequencing; (b)
chromosome 5 analysed by NG sequencing; (c) chromosome 3 analysed by aGCH; (d) chromosome 5 analysed by aCGH.
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DNA extracted from snap frozen versus FFPE material
from the same lung squamous cell carcinomas (Figure 3).
As previously shown by Schweiger et al. the matching
fresh and ﬁxed copy number karyograms for some of
the samples were almost identical even when examined
at high resolution. For other samples, the positions of
regions of CNV in the ﬁxed samples were identical to
Figure 3. Copy number karyograms of DNA extracted from snap frozen and FFPE tissue. Representative individual chromosome plots for two lung
squamous cell carcinoma patients (LS041 and LS043) are shown. (a) LS041 snap frozen chromosome 1; (b) LS041 FFPE chromosome 1; (c) LS043
snap-frozen chromosome 9; (d) LS043 FFPE chromosome 9.
Figure 2. Comparison of copy number analysis by (a) sequencing and (b) a digital PCR method (MCC). The 88 MCC markers between 165 and 182
Mb of chromosome 3 of the HONE-1 cell line were analysed and compared to the sequence-based copy number data from the same region.
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greater. For example, in the fresh-frozen sample, LS043,
shown in Figure 3, the distal 9 Mb of 9p has a tu-
mour:normal ratio of 1.1:1, while the rest of the 9p arm
has a ratio of 0.82:1. In the FFPE sample the two regions
are in the same position, but have ratios of 1.51:1 and
0.75:1, respectively. This diﬀerence is probably due to
the removal of non-cancerous cells (i.e. stromal cells, in-
ﬂammatory cells and endothelial cells) by macrodissection
in the ﬁxed samples.
The eﬀect of using decremental amounts of starting DNA
Due to the diﬃculty in obtaining large amounts of good
quality DNA from many clinical samples, especially ﬁxed
archival surgical and biopsy specimens, we undertook to
investigate the minimum amount of DNA that is needed
to produce acceptable sequence data for copy number
analysis. We performed a series of dilutions of DNA
from one of the frozen tumour samples and one of the
FFPE samples, so that sequencing libraries were generated
from 400ng, 200ng, 100ng, 50ng, 10ng and 5ng of
starting DNA, compared to Illumina’s recommended
1mg. As all the libraries appeared to be within normal
parameters as judged by Agilent readings, only those
prepared from 50ng, 10ng and 5ng were sequenced.
While it was diﬃcult to accurately titrate the lower con-
centration libraries to give a consistent number of
sequencing reads, and some samples gave a low percentage
of alignable reads, the karyograms produced were almost
identical to those made under Illumina’s recommended
conditions suggesting that copy number data could be
obtained from nanogram quantities of DNA isolated
from tissue sections of a FFPE block (Figure 4). To
conﬁrm this in a real sample, we obtained FFPE blocks
of sequential biopsies and surgical specimens from a
patient with multifocal oral cancer who has been under
the care of the local maxillo-facial unit for several years.
Speciﬁcally, we obtained blocks for (i) a biopsy of a
tumour in the left tongue in May 2007, (ii) a biopsy of
dysplasia in the right ﬂoor of the mouth in June 2008, (iii)
a wide excision specimen of the same dysplasia in July
2008 and (iv) four distinct specimens of tumour-associated
dysplasia obtained from a further anterior ﬂoor of mouth
surgical resection in August 2009. DNA was isolated from
macrodissected dysplastic and tumour tissue and libraries
were prepared from template DNA ranging from 55 to
270ng. The karyograms were mostly normal (results not
shown): the most notable feature was gain of 10p, which
was common to all lesions. The synchronous biopsies
obtained in the surgical ﬁeld in August 2009 carried an
8Mb region of ampliﬁcation of distal 9p in addition to
gain of 10p (Figure 5).
Feasibility of multiplexing
We investigated sequencing various numbers of pooled
libraries together in order to gain an understanding of
the quality of data obtainable from diﬀerent levels of
reagent and machine capacity investment. The initial ex-
periment using the LUDLU-1:AGLCL cell line pair was
performed using one eighth of an Illumina GAII run and
produced 7897570 uniquely aligning reads. Of these,
tagging indicated that 2547384 were from LUDLU1. A
total of 2500000 reads of 45bp (51bp – 6bp tag) repre-
sents 113 Mb, or 0.04 coverage. The 206 CNV regions
were detected with mean size of 15 Mb and a smallest
detectable size of 15 Kb.
For the subsequent experiment using DNA from
snap-frozen tumour:normal pairs, the level of multiplexing
was increased so that 10 samples (5 pairs) were pooled and
analysed together on one eighth of an Illumina GAII run.
Between 847576 and 1321486 reads per sample were
obtained. Between 57 and 115 copy number variation
regions were detected, averaging between 26 and 58 Mb
in size, with a smallest detectable region between 0.9 and
1.5 Mb. This experiment was duplicated and the reads
from each sequencing run combined to give between
1873100 and 2328268 reads per sample (0.028–0.035
coverage). The overall CNV pattern of each sample
remained unchanged (Figure 6a and b), but the
DNAcopy algorithm was able to detect smaller regions
of copy number variation, between 89 and 200 Kb. As a
result, the number of observed regions increased to
between 81 and 187.
To determine how little data would give reproducible
results, 90% of the reads from one of the frozen samples
(LS010) were randomly removed in silico, leaving 136405
tumour reads or 0.002 coverage. This is an approximate
simulation of running 80 tagged samples on one lane, or
0.15% of the sequencer’s total capacity. Currently, this is
not technically feasible, but may be achievable in the near
future as methods such as DNA Sudoku mature (20).
Unsurprisingly, all ﬁne scale data were lost, the smallest
region of variation being detected being 5 Mb. It was still
perfectly possible to see large-scale aberrations such as the
gain or loss of whole chromosomal arms (Figure 6c), sug-
gesting that this methodology could still provide useful
data even when highly multiplexed.
To further explore the theoretical limits of multiplexing,
a series of simulations were performed using the
LUDLU-1:AGLCL cell line pair. An additional 7.4
million AGLCL reads were sequenced, giving a total of
12218030 reads. Reads were randomly stripped away
in silico from both samples, resulting in ﬁve ﬁles of
AGLCL reads ranging between 2441867 and 12218030
and 20 ﬁles of LUDLU-1 reads ranging between 127421
and 2551569. 127421 reads is <1% of the standard
output from one lane of an Illumina GAII during our
experiments. Every combination of these two samples
was then analysed, using LUDLU-1 as the test and
AGLCL as the reference sample, and keeping the
window sizes equivalent to 200 LUDLU-1 reads. The
results are shown in Figure 7. The number of reference
reads appeared to have almost no eﬀect on either the
number of CNVs, mean size or smallest detectable CNV.
Not surprisingly, the number of LUDLU-1 reads, and
hence the size of the windows used had a much greater
eﬀect. Resolution gradually decreased alongside read
number, but with a sudden decrease once read numbers
dropped below 500000. It may be that this is the point at
which a window size of 200 reads is bigger than many of
the actual CNVs from this sample.
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We have demonstrated that NG sequencing platforms can
be used in a high-throughput, cost-eﬀective manner to
elucidate copy number information from a variety of
DNA sources, including cell lines, frozen tumour
samples and FFPE material. We have shown that good
quality data can be obtained when multiplexing up to 10
samples on one lane of an Illumina GAII. We have shown
that the method is reproducible, and that the resolution is
highly ﬂexible and adjustable. The resolution has been
shown to be comparable with aCGH when performed at
low levels of multiplexing and has a high degree of correl-
ation. NG sequencing also produces much more data than
a comparable investment in a PCR-based method such as
loss of heterozygosity (LOH) analysis or MCC when
performed at higher levels of multiplexing. Sequence
data and MCC does show a strong correlation, but
not as strong as that between sequencing and aCGH.
We have concentrated on tumour samples, but
the method is equally applicable to studies of CNV in
constitutional DNA. In fact, the data are much easier to
interpret when all the cells in a sample have the same
genotype.
Currently, the leading technology for investigating
CNV is aCGH. However, limitations remain for certain
applications. aCGH has proved diﬃcult to use with DNA
from FFPE samples. Typically, researchers have had to
devise ingenious upstream methods in order to study
archival material (21). Also, aCGH typically requires
microgram quantities of DNA. When smaller samples
are studied, a whole-genome ampliﬁcation step is general-
ly incorporated (22). Our method requires almost no extra
ﬁne tuning as we moved from cell line DNA to nanogram
amounts of DNA from archival FFPE material, showing
that neither a large amount of template or a whole genome
ampliﬁcation step are required. In addition, although we
have only demonstrated the use of these data for copy
number analysis, each lane of sequencing generates in
the region of 700 Mb of sequence data, which can be
analysed for other purposes such as searching for genetic
variants or viral infection.
Previous studies have used read depth of sequence to
examine copy number but with ideal reaction conditions
and greater depth of coverage (2–5). Other studies have
explored the limits of this technology further, by use of
multiplexing (23) or by using DNA from FFPE samples
Figure 4. NG sequencing-based copy number karyograms using decremental amounts of starting DNA, i.e. (a)1mg, (b) 50ng, (c) 10ng and (d) 5ng.
The copy number proﬁles for chromosome 3 using genomic DNA from the FFPE squamous cell carcinoma LS043 are shown here. Similar results
were obtained for the other chromosomes and also using the fresh frozen sample LS010 (not shown).
PAGE 7 OF 11 Nucleic Acids Research, 2010,Vol.38, No. 14 e151Figure 5. Generation of copy number karyograms from small clinical samples. Chromosomes 9 and 10 copy number proﬁles of DNA from four
sequential FFPE specimens obtained from diﬀerent areas of the oral cavity of the same patient (PG019) over a two year period. The samples shown
are (a) PG019-1, a biopsy from May 2007; (b) PG019-4, a biopsy from June 2008; (c) PG019-5, wide local excision from July 2008; (d) specimen from
surgical resection from August 2009. All samples show a similar gain of the short arm of chromosome 10. PG019-8 shows a discreet ampliﬁcation in
9p: this ampliﬁcation was detected in three additional samples from the August 2009 surgical resection (data not shown).
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further push the limits as to the minimum amounts of
starting DNA required. The multiplexing aspect is import-
ant because it allows researchers to tailor their study
design according to the number of samples, desired reso-
lution and available resources. The same sequencing
library can be used for a 1Kb or a 10Mb resolution ex-
periment. The only diﬀerence is the amount of sequencing
required. Libraries can be aliquoted for use a number of
times so that samples can be initially screened cheaply at
low resolution and then further examined at high reso-
lution at a later date and with no additional preparation.
Data from two duplicate experiments on the same sample
can be merged to double the coverage.
We have demonstrated that sequencing libraries can be
constructed starting with nanogram quantities of DNA
and, by combining individually tagged libraries, copy
number karoygrams can be generated from 10 samples
in a single Illumina sequencing run, with the theoretical
possibility of extending this number up to at least 80.
Besides demonstrating this high-throughput potential,
we have also conﬁrmed the observations of Schweiger
et al. (6) that DNA isolated from FFPE material can
serve as a template to create sequencing libraries for NG
sequencing. We have substantially extended the range of
samples that can be studied by reducing the amount of
template required for library construction from 1.5mgt o
less than 100ng. This is an important practical consider-
ation because it allows minute tissue samples such as
biopsies to be analysed. Not only are biopsies small but
also the way they are obtained from patients often incorp-
orates underlying stroma, requiring micro-dissection to
increase the proportion of abnormal epithelial cells,
decreasing the amount of DNA template still further.
However these diﬃculties must be overcome, as analysis
of biopsies is essential for both basic and translational
cancer research.
In attempting to identify the genomic drivers of malig-
nant tumour initiation and progression of upper
aerodigestive cancer, we have used a number of molecular
genetic techniques to compare candidate regions, genes
and chromosomes of pre-invasive lesions, obtained as
Figure 6. The eﬀect of increased multiplexing. Sequencing was performed using 5 and 10 samples per lane of an Illumina GAII. Shown here is
chromosome 1 from sample LS010 at the level of (a) ﬁve samples per lane generating 2330765 sequence reads for this sample or 0.035 genomic
coverage; (b) 10 samples per lane generating 1091212 reads or 0.016 coverage and (c)a nin silico simulation of 80 samples per lane generating
136405 reads or 0.002 coverage.
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site of the earlier pre-invasive lesions (24–26). In this
study, we have used NG sequencing to generate whole
genome copy number karyotypes of biopsies and
tumours obtained in a chronologic series from a patient
with oral cancer. The patient’s cancer has had a relatively
indolent disease course reﬂected by several invasive
tumours and dysplastic lesions but no metastatic disease.
The karyotypes of the tumour and dysplastic lesions
obtained carry relatively few gains and losses compared
other the other carcinoma karyograms we examined. This
may be a reﬂection of the tumour’s histology, a verrucous
squamous cell carcinoma, whose benign growth pattern
may in turn be a consequence of a relatively normal
genotype. However, all specimens examined carry gain
of the short arm of chromosome 10 indicating a clonal
origin. Those obtained from the most recent surgery
demonstrated genomic progression, having acquired amp-
liﬁcation of distal 9p, an 8 Mb region encompassing
63 predicted genes (27). 9p loss has been associated with
tumour progression (28,29), but gain in this region so far
has not.
Besides the analysis of biopsies for laboratory studies of
clonality and the genomics of tumour progression, the
genomic assessment of tumours via the preliminary diag-
nostic biopsy may a be a useful supplement to routine
histopathology, as knowledge of a tumour’s genotype
can provide information for prognosis and treatment
response (30). The international initiatives to document
cancer genomes (http://www.icgc.org/, http://cancergen
ome.nih.gov/about/index.asp) will substantially augment
our current knowledge. We have used ﬁxed archival spe-
cimens in this study, but the current samples of each new
patient are also ﬁxed as part of routine clinical practice,
and the ability to generate whole-genome information
from the ﬁxed samples obtained as demonstrated here,
indicates how cataloguing genome architecture could be
become part of the repertoire of diagnostic tests for
cancer.
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Figure 7. Simulated data showing the eﬀect of increased multiplexing.
Twenty diﬀerent numbers of LUDLU-1 reads between 127421 and
2551569 were compared to ﬁve diﬀerent numbers of AGLCL
reads between 2441867 and 12218030. Shown here are: (a) the
mean CNV size; (b) the number of CNVs detected; (c) the smallest
detectable CNV.
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